Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma
- Registration Number
- NCT01264640
- Lead Sponsor
- University of Rostock
- Brief Summary
The impact of anti-platelet drugs on the concentrations of Brain-derived neurotrophic factor (BDNF) in human plasma and serum is unknown. It is the aim of this study to investigate the impact of a single dose of Aspirin (500 mg) or Clopdigrel (600 mg) on the concentrations of Brain-derived neurotrophic factor (BDNF) in plasma and serum of healthy volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 25
Inclusion Criteria
- Age 18-50 years
- Gender: Male
Exclusion Criteria
- Any acute disease
- Any chronic disease
- Any medication
- Allergies / Intolerance in association with Aspirin or Clopidogrel
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Aspirin and Clopidogrel Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
- Primary Outcome Measures
Name Time Method BDNF plasma and serum concentration 24 hours after Aspirin or Clopidgrel intake 24 hours
- Secondary Outcome Measures
Name Time Method 5-HT and TGF-beta concentrations 24 hours after Aspirin or Clopidgrel intake 24 hours
Trial Locations
- Locations (1)
Dep. of Pneumology, University of Rostock
🇩🇪Rostock, Mecklenburg-Vorpommern, Germany